ALT5 Sigma (AIFC) Competitors $0.89 +0.02 (+2.05%) As of 05/22/2026 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AIFC vs. OCGN, FULC, EPRX, ZURA, and AUTLShould you buy ALT5 Sigma stock or one of its competitors? MarketBeat compares ALT5 Sigma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALT5 Sigma include Ocugen (OCGN), Fulcrum Therapeutics (FULC), Eupraxia Pharmaceuticals (EPRX), Zura Bio (ZURA), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. AIFC vs. OCGNAIFC vs. FULCAIFC vs. EPRXAIFC vs. ZURAAIFC vs. AUTLHow does ALT5 Sigma compare to Ocugen?ALT5 Sigma (NASDAQ:AIFC) and Ocugen (NASDAQ:OCGN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Does the media refer more to AIFC or OCGN? In the previous week, ALT5 Sigma had 1 more articles in the media than Ocugen. MarketBeat recorded 1 mentions for ALT5 Sigma and 0 mentions for Ocugen. Ocugen's average media sentiment score of 0.00 beat ALT5 Sigma's score of -0.47 indicating that Ocugen is being referred to more favorably in the news media. Company Overall Sentiment ALT5 Sigma Neutral Ocugen Neutral Which has preferable valuation and earnings, AIFC or OCGN? Ocugen has lower revenue, but higher earnings than ALT5 Sigma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALT5 Sigma$24.84M5.03-$344.51MN/AN/AOcugen$4.41M102.86-$67.85M-$0.24N/A Is AIFC or OCGN more profitable? Ocugen has a net margin of -1,192.18% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets ALT5 Sigma-2,483.94% -68.25% -62.43% Ocugen -1,192.18%-127,987.80%-135.48% Which has more volatility & risk, AIFC or OCGN? ALT5 Sigma has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market. Do insiders & institutionals believe in AIFC or OCGN? 6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by company insiders. Comparatively, 4.0% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer AIFC or OCGN? Ocugen has a consensus price target of $9.75, indicating a potential upside of 627.61%. Given Ocugen's stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Ocugen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryOcugen beats ALT5 Sigma on 10 of the 14 factors compared between the two stocks.How does ALT5 Sigma compare to Fulcrum Therapeutics?ALT5 Sigma (NASDAQ:AIFC) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Is AIFC or FULC more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Fulcrum Therapeutics' return on equity of -27.80% beat ALT5 Sigma's return on equity.Company Net Margins Return on Equity Return on Assets ALT5 Sigma-2,483.94% -68.25% -62.43% Fulcrum Therapeutics N/A -27.80%-26.32% Which has more volatility & risk, AIFC or FULC? ALT5 Sigma has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.02, meaning that its share price is 202% more volatile than the broader market. Which has preferable valuation and earnings, AIFC or FULC? Fulcrum Therapeutics has higher revenue and earnings than ALT5 Sigma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALT5 Sigma$24.84M5.03-$344.51MN/AN/AFulcrum Therapeutics$80M5.47-$74.88M-$1.15N/A Does the media refer more to AIFC or FULC? In the previous week, ALT5 Sigma had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 1 mentions for ALT5 Sigma and 0 mentions for Fulcrum Therapeutics. ALT5 Sigma's average media sentiment score of -0.47 beat Fulcrum Therapeutics' score of -1.00 indicating that ALT5 Sigma is being referred to more favorably in the media. Company Overall Sentiment ALT5 Sigma Neutral Fulcrum Therapeutics Negative Do insiders & institutionals believe in AIFC or FULC? 6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by company insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer AIFC or FULC? Fulcrum Therapeutics has a consensus price target of $19.00, indicating a potential upside of 189.19%. Given Fulcrum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Fulcrum Therapeutics is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Fulcrum Therapeutics 2 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryFulcrum Therapeutics beats ALT5 Sigma on 12 of the 14 factors compared between the two stocks.How does ALT5 Sigma compare to Eupraxia Pharmaceuticals?ALT5 Sigma (NASDAQ:AIFC) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation. Is AIFC or EPRX more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ALT5 Sigma-2,483.94% -68.25% -62.43% Eupraxia Pharmaceuticals N/A -87.56%-51.20% Do institutionals & insiders hold more shares of AIFC or EPRX? 6.3% of ALT5 Sigma shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, AIFC or EPRX? Eupraxia Pharmaceuticals has lower revenue, but higher earnings than ALT5 Sigma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALT5 Sigma$24.84M5.03-$344.51MN/AN/AEupraxia PharmaceuticalsN/AN/A-$38.58M-$1.05N/A Which has more volatility and risk, AIFC or EPRX? ALT5 Sigma has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Do analysts prefer AIFC or EPRX? Eupraxia Pharmaceuticals has a consensus target price of $18.33, suggesting a potential upside of 158.22%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Eupraxia Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89 Does the media refer more to AIFC or EPRX? In the previous week, Eupraxia Pharmaceuticals had 11 more articles in the media than ALT5 Sigma. MarketBeat recorded 12 mentions for Eupraxia Pharmaceuticals and 1 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of -0.47 beat Eupraxia Pharmaceuticals' score of -0.53 indicating that ALT5 Sigma is being referred to more favorably in the media. Company Overall Sentiment ALT5 Sigma Neutral Eupraxia Pharmaceuticals Negative SummaryEupraxia Pharmaceuticals beats ALT5 Sigma on 8 of the 14 factors compared between the two stocks.How does ALT5 Sigma compare to Zura Bio?Zura Bio (NASDAQ:ZURA) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends. Which has more risk and volatility, ZURA or AIFC? Zura Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Which has preferable earnings and valuation, ZURA or AIFC? Zura Bio has higher earnings, but lower revenue than ALT5 Sigma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZura BioN/AN/A-$99.35M-$1.09N/AALT5 Sigma$24.84M5.03-$344.51MN/AN/A Is ZURA or AIFC more profitable? Zura Bio has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Zura Bio's return on equity of -55.74% beat ALT5 Sigma's return on equity.Company Net Margins Return on Equity Return on Assets Zura BioN/A -55.74% -48.07% ALT5 Sigma -2,483.94%-68.25%-62.43% Do analysts recommend ZURA or AIFC? Zura Bio presently has a consensus price target of $10.75, suggesting a potential upside of 146.56%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts plainly believe Zura Bio is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zura Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do insiders & institutionals hold more shares of ZURA or AIFC? 61.1% of Zura Bio shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 14.2% of Zura Bio shares are held by insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer ZURA or AIFC? In the previous week, Zura Bio had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for ALT5 Sigma. Zura Bio's average media sentiment score of 0.05 beat ALT5 Sigma's score of -0.47 indicating that Zura Bio is being referred to more favorably in the media. Company Overall Sentiment Zura Bio Neutral ALT5 Sigma Neutral SummaryZura Bio beats ALT5 Sigma on 12 of the 14 factors compared between the two stocks.How does ALT5 Sigma compare to Autolus Therapeutics?Autolus Therapeutics (NASDAQ:AUTL) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Which has more risk and volatility, AUTL or AIFC? Autolus Therapeutics has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Which has preferable valuation & earnings, AUTL or AIFC? Autolus Therapeutics has higher revenue and earnings than ALT5 Sigma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$75.39M6.00-$287.53M-$1.09N/AALT5 Sigma$24.84M5.03-$344.51MN/AN/A Does the media prefer AUTL or AIFC? In the previous week, Autolus Therapeutics had 9 more articles in the media than ALT5 Sigma. MarketBeat recorded 10 mentions for Autolus Therapeutics and 1 mentions for ALT5 Sigma. Autolus Therapeutics' average media sentiment score of 0.45 beat ALT5 Sigma's score of -0.47 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Autolus Therapeutics Neutral ALT5 Sigma Neutral Do analysts rate AUTL or AIFC? Autolus Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 414.71%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do insiders and institutionals hold more shares of AUTL or AIFC? 72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is AUTL or AIFC more profitable? Autolus Therapeutics has a net margin of -311.98% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Autolus Therapeutics-311.98% -128.59% -46.25% ALT5 Sigma -2,483.94%-68.25%-62.43% SummaryAutolus Therapeutics beats ALT5 Sigma on 14 of the 15 factors compared between the two stocks. Get ALT5 Sigma News Delivered to You Automatically Sign up to receive the latest news and ratings for AIFC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIFC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIFC vs. The Competition ExportMetricALT5 SigmaFIN IndustryFinance SectorNASDAQ ExchangeMarket Cap$122.40M$7.10B$13.57B$12.31BDividend YieldN/A5.70%5.82%5.31%P/E RatioN/A92.4923.9525.66Price / Sales5.0310.19150.6283.75Price / CashN/A69.7920.2856.72Price / Book0.142.682.157.14Net Income-$344.51M$309.43M$1.13B$335.72M7 Day Performance-11.12%-1.38%0.88%3.03%1 Month Performance4.41%-2.50%0.00%2.88%1 Year Performance-89.98%15.19%12.02%35.20% ALT5 Sigma Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIFCALT5 Sigma0.185 of 5 stars$0.89+2.0%N/A-87.6%$122.40M$24.84MN/A170Earnings ReportOCGNOcugen1.5862 of 5 stars$1.47flat$9.75+563.3%+46.6%$497.62M$4.41MN/A80FULCFulcrum Therapeutics1.5467 of 5 stars$7.25+4.2%$19.00+162.1%+7.4%$483.07M$80MN/A100Negative NewsEPRXEupraxia Pharmaceuticals2.231 of 5 stars$7.55-0.8%$15.00+98.7%+87.6%$456.25MN/AN/A29Analyst ForecastAnalyst RevisionZURAZura Bio3.1563 of 5 stars$4.80+1.1%$10.75+124.0%+319.2%$455.42MN/AN/A3Options Volume Related Companies and Tools Related Companies OCGN Alternatives FULC Alternatives EPRX Alternatives ZURA Alternatives AUTL Alternatives LXEO Alternatives KMDA Alternatives LYEL Alternatives EOLS Alternatives ADCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AIFC) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALT5 Sigma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ALT5 Sigma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
